SMAD family member 9Genealiases: MADH6 · MADH9 · PPH2 · SMAD8 · SMAD8/9 · SMAD8A
Q-omics provides the consensus-scored SMAD9 profile across patient tissues and cancer cell-line models. SMAD9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SMAD9 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SMAD9 RNA expression shows 19,926 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where SMAD9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMAD9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMAD9 survival associations across molecular data types. SMAD9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMAD9 RNA expression–survival associations across cancer types. High SMAD9 expression shows unfavorable associations in UVM, but favorable associations in KIRC, LUAD, CHOL, LGG and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SMAD9 RNA expression.
This table summarizes SMAD9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SMAD9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMAD9 shows lower tumor expression in THCA, KICH, LUSC, BLCA, LUAD and BRCA. The THCA box plot shows higher SMAD9 RNA expression in normal versus tumor tissue (log2 FC = −2.917, t-test p < 0.001).
This table shows molecular features associated with SMAD9 in patient tissues and cancer cell lines. In patient samples, SMAD9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMAD9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
